Navigating the complexity of intracranial solitary fibrous tumors: A single-center experience

Solitary fibrous tumor (SFT) is a very uncommon central nervous system (CNS) neoplasm and accounts for less than 1% of primary CNS tumors. After the World Health Organization’s reclassification in 2021, SFT is a rare novel entity. Since SFT is a slow-growing, vascular, and aggressive tumor, it has a likelihood of local recurrence as well as distant metastasis. Surgery remains the main treatment modality, whereas postoperative radiation therapy (PORT) benefits in local control. In this case series, we analyzed the data on intracranial SFT retrospectively among patients who had presented to us in 2024 and underwent surgery in the same year. We reviewed the primary surgery that was done, the extent of resection, clinical presentation, radiological findings, tumor size, post-operative radiotherapy, and a brief follow-up. In this study, 4 cases of intracranial SFT have been discussed along with a review of the literature. Although surgery remains the main treatment domain, PORT is a part of adjuvant treatment in all grades of SFT for controlling local recurrence. Because of the rarity of the disease, most of the previous studies are single-center, and the role of post-operative radiotherapy is in controlling local recurrence; however, conflicting.